Cargando…
Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases
Sickle cell disease (SCD), also known as sickle cell anemia (SCA) is one of the structural hemoglobinopathies that occurs due to a single nucleotide mutation from GAG to GTG, which changes the amino acid of a β-globin chain of hemoglobin (Hb) from glutamate to valine. This singular mutation results...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167986/ https://www.ncbi.nlm.nih.gov/pubmed/35677416 http://dx.doi.org/10.1016/j.heliyon.2022.e09630 |
_version_ | 1784720899241410560 |
---|---|
author | Alabi, Oladeji John Adegboyega, Fikayo Noah Olawoyin, Dolapo Samuel Babatunde, Oluwakemi Arinola |
author_facet | Alabi, Oladeji John Adegboyega, Fikayo Noah Olawoyin, Dolapo Samuel Babatunde, Oluwakemi Arinola |
author_sort | Alabi, Oladeji John |
collection | PubMed |
description | Sickle cell disease (SCD), also known as sickle cell anemia (SCA) is one of the structural hemoglobinopathies that occurs due to a single nucleotide mutation from GAG to GTG, which changes the amino acid of a β-globin chain of hemoglobin (Hb) from glutamate to valine. This singular mutation results to disorderliness in red blood cells (RBCs) with advent of changes in RBC morphology and other pathological conditions. In the 1980s, intermittent red blood cell transfusions, opioids, and penicillin prophylaxis were the only available therapy for SCA and were commonly reserved for acute, life threatening complications. So far, the US Food and Drug Administration (FDA) has granted a total of four drugs approval for the prophylaxis and treatment of the clinical complications of SCD. Due to limitations (adherence, safety, adverse effects) of existing therapies in the prophylaxis and treatment of SCD complications in Nigerian children and their inaccessibility to approved drugs, the present study discusses the therapeutic effects of readily available functional food as one of the therapies or an adjunct therapy to tackle the sickle cell crisis in Nigerian Children. |
format | Online Article Text |
id | pubmed-9167986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-91679862022-06-07 Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases Alabi, Oladeji John Adegboyega, Fikayo Noah Olawoyin, Dolapo Samuel Babatunde, Oluwakemi Arinola Heliyon Review Article Sickle cell disease (SCD), also known as sickle cell anemia (SCA) is one of the structural hemoglobinopathies that occurs due to a single nucleotide mutation from GAG to GTG, which changes the amino acid of a β-globin chain of hemoglobin (Hb) from glutamate to valine. This singular mutation results to disorderliness in red blood cells (RBCs) with advent of changes in RBC morphology and other pathological conditions. In the 1980s, intermittent red blood cell transfusions, opioids, and penicillin prophylaxis were the only available therapy for SCA and were commonly reserved for acute, life threatening complications. So far, the US Food and Drug Administration (FDA) has granted a total of four drugs approval for the prophylaxis and treatment of the clinical complications of SCD. Due to limitations (adherence, safety, adverse effects) of existing therapies in the prophylaxis and treatment of SCD complications in Nigerian children and their inaccessibility to approved drugs, the present study discusses the therapeutic effects of readily available functional food as one of the therapies or an adjunct therapy to tackle the sickle cell crisis in Nigerian Children. Elsevier 2022-06-02 /pmc/articles/PMC9167986/ /pubmed/35677416 http://dx.doi.org/10.1016/j.heliyon.2022.e09630 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Article Alabi, Oladeji John Adegboyega, Fikayo Noah Olawoyin, Dolapo Samuel Babatunde, Oluwakemi Arinola Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases |
title | Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases |
title_full | Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases |
title_fullStr | Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases |
title_full_unstemmed | Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases |
title_short | Functional foods: promising therapeutics for Nigerian Children with sickle cell diseases |
title_sort | functional foods: promising therapeutics for nigerian children with sickle cell diseases |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167986/ https://www.ncbi.nlm.nih.gov/pubmed/35677416 http://dx.doi.org/10.1016/j.heliyon.2022.e09630 |
work_keys_str_mv | AT alabioladejijohn functionalfoodspromisingtherapeuticsfornigerianchildrenwithsicklecelldiseases AT adegboyegafikayonoah functionalfoodspromisingtherapeuticsfornigerianchildrenwithsicklecelldiseases AT olawoyindolaposamuel functionalfoodspromisingtherapeuticsfornigerianchildrenwithsicklecelldiseases AT babatundeoluwakemiarinola functionalfoodspromisingtherapeuticsfornigerianchildrenwithsicklecelldiseases |